We sought to examine the short-and long-term outcomes of patients who developed contrast-induced acute kidney injury (CI-AKI; defined as an increase in serum creatinine of ≥0.5 mg/dL or a 25% relative rise within 48 h after contrast exposure) from the large-scale HORIZONS-AMI trial.
Introduction
Contrast-induced acute kidney injury (CI-AKI) after percutaneous coronary intervention (PCI) is associated with significant in-hospital as well as long-term morbidity and mortality. The incidence of CI-AKI varies from 2% in the general population to over 50% in high-risk groups. 1 Given this, individual risk factors that predict CI-AKI have been identified, and cumulative risk scores developed. 1, 2 Patients at higher risk include those with baseline chronic kidney disease, diabetes mellitus, congestive heart failure (CHF), hypotension, and anaemia; procedural variables such as use of intra-aortic balloon pump (IABP) and contrast volume also contribute. Efforts to modify the risk of CI-AKI have included the investigation of various hydration strategies, N-acetylcysteine use, different contrast agents, haemofiltration protocols, and most recently statin therapy with often mixed and conflicting results. 3 -19 The Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial demonstrated lower rates of major bleeding and mortality with bivalirudin compared with unfractionated heparin (UFH) and glycoprotein IIb/ IIIa inhibitors (GPI). 20, 21 Patients with acute ST-segment elevation myocardial infarction (STEMI) are an especially high-risk group for CI-AKI and subsequent adverse events; only a few studies with small sample sizes have examined the impact of CI-AKI in this specific population. 22, 23 Here, we report 3 year, prospective data on outcomes in a large, primary cohort of STEMI patients who developed CI-AKI, as well as the predictive variables for CI-AKI in this cohort.
. 
Methods
Patient population, randomization, and study protocol
The design, inclusion and exclusion criteria, and results of the HORIZONS-AMI trial have been previously published. 20, 21, 24 Briefly, HORIZONS-AMI was a prospective, open-label, 2 × 2 factorial randomized trial involving patients with STEMI who were undergoing primary PCI as a management strategy. A total of 3602 patients with STEMI presenting within 12 h of symptom onset were prospectively randomized to UFH plus the routine use of a GPI vs. bivalirudin plus provisional use of a GPI reserved for pre-defined refractory thrombotic complications. After angiography, eligible patients were randomly assigned to either a TAXUS Express paclitaxel-eluting stent (Boston Scientific, Natick, MA, USA) or to an otherwise identical Express bare metal stent (Boston Scientific). Serum creatinine measurement was recommended per protocol at baseline as part of the initial blood work obtained in the emergency room, and daily post-procedure for a minimum of 2 days; if the serum creatinine was elevated by ≥0.3 mg/dL from baseline, it was recommended to obtain daily creatinine levels until renal function demonstrated improvement. Creatinine clearance was calculated by applying the Cockroft -Gault formula. Data were not collected regarding need for haemodialysis during or after initial hospitalization. The protocol allowed for the use of the following contrast types: the iso-osmolar agent, iodixanol, or the low-osmolar agents: iopamidol, ioxaglate, iohexol, iopromide, iotrolan, and ioversol. There was no exclusion based on creatinine clearance or haemodialysis at baseline in the HORIZONS-AMI trial. However, patients with a history of dialysis were excluded from this analysis.
Study endpoints and definitions
The HORIZONS-AMI trial was powered for two 30-day endpoints: major bleeding (not related to CABG) and combined net adverse clinical events (NACE, consisting of major bleeding not related to CABG or a composite of major adverse cardiac events (MACE), including death, reinfarction, target vessel revascularization (TVR) for ischaemia, or stroke). 20, 21, 24 Outcomes for the primary endpoints were assessed out to 3 years. An independent clinical events committee blinded to treatment assignment adjudicated all events. Contrast-induced acute kidney injury was defined as an increase in serum creatinine of ≥0.5 mg/dL, or a 25% relative rise in creatinine, within 48 h after contrast exposure. 25 
Statistical analysis
All analyses are by intention to treat. Chi-square tests were used to compare categorical variables. Continuous variables are presented as medians with inter-quartile ranges and were compared using the Wilcoxon rank-sum test. Follow-up analysis was performed using time-to-event data (for which patients were censored at the time of withdrawal from the study or at the last follow-up), with the event rates estimated by Kaplan-Meier methods and compared with the log-rank test. Additionally, a landmark analysis was conducted for all major endpoints, which included all patients without events beginning at 30 days and continuing to last follow-up available. A stepwise logistic regression model with an entry and exit level of significance of 0.1 was used to identify independent predictors of CI-AKI. Cox regression models were used to identify independent predictors of NACE, MACE, major bleeding, and mortality at 3 years. The number of variables included was carefully chosen based on the total number of events to ensure parsimony of each model (see footnote to respective table for complete list of variables included). The final Cox models used were selected using a stepwise selection algorithm, with an entry and exit level of significance of 0.10. All statistical analyses were performed by SAS version 9.2 (SAS Institute, Cary, NC, USA). Finally, a propensitymatched cohort was created for CI-AKI matching on the variables of age, gender, diabetes mellitus, smoking, Killip class .1, LVEF, and anaemia.
Results
Incidence and predictors of contrast-induced acute kidney injury Table 2) . When the patients with baseline chronic kidney disease were excluded, contrast volume, LAD infarct-related artery, age, and history of CHF remained independent predictors of CI-AKI. We applied the Mehran and Marenzi scores for prediction of CI-AKI after percutaneous intervention. The Mehran risk score assigns points for the risk factors: hypotension, use of intra-aortic balloon pump, CHF, age .75 years, anaemia, diabetes mellitus, contrast volume, and serum creatinine or chronic kidney disease. 1 Patients were stratified into low-risk (≤5 points), moderate-risk (6-10 points), high-risk (11-15 points), and very high-risk (≥16 points) groups. Rates of CI-AKI by group were low risk (12.4%, 127/1024), moderate risk (14.5%, 165/1141), high risk (24.1%, 92/ 381), and very high risk (37.0%, 37/100) (P , 0.0001). The area under the curve (AUC) of the model was 0.60 (95% CI, 0.57-0.63). The Marenzi score assigns points for the variables: age ≥ 75, anterior myocardial infarction, time to reperfusion ≥6 h, contrast agent volume ≥ 300 mL, and use of the intra-aortic balloon pump. 22 Rates of CI-AKI by group were Score 0, 10% (82/818); A. Narula et al.
had significantly higher rates of definite or probable stent thrombosis (7.1 vs. 4.5%; P ¼ 0.03). In a landmark analysis beginning at 30 days, patients who suffered CI-AKI had a continuing late hazard for adverse cardiovascular events and mortality compared with those that did not (Figure 1 A-D) . These findings were confirmed in a propensity-matched cohort, with significantly higher rates of NACE, MACE, cardiac death, and mortality at both short-and long-term follow-up ( Table 3) . Furthermore, in multivariable analyses, CI-AKI was an independent predictor of NACE (HR, 1.53; 95% CI, 1.23-1.90; P ¼ 0.0002), MACE (HR, 1.56; 95% CI, 1.23 -1.98; P ¼ 0.0002), non-CABG major bleeding (HR, 2.07; 95% CI, 1.57-2.73; P , 0.0001), and mortality (HR, 1.80; 95% CI, 1.19-2.73; P ¼ 0.005) at 3-year follow-up ( Table 4) .
Impact of contrast type on outcomes
Of patients meeting inclusion criteria for this analysis with data on contrast type, 1380 of 1832 (75.3%) received low-osmolar contrast, while 452/1832 (24.7%) received iso-osmolar contrast. There were no significant differences between rates of CI-AKI by type of contrast used (low-osmolar vs. iso-osmolar, 15.6 vs. 15.3%; P ¼ 0.87). Patients who received low-osmolar contrast had lower 30-day rates of NACE (10.2 vs. 14.4%; P ¼ 0.01), MACE (3.8 vs. 7.1%; P ¼ 0.003), and stent thrombosis (1.8 vs. 3.5%; P ¼ 0.04), but these differences did not persist at 3-year follow-up. They also had lower 30-day rates of ischaemic TVR (1.7 vs. 3.8%; P ¼ 0.01); this difference was not significant at 3-year follow-up (13.9 vs. 13.9%; P ¼ 0.89). Rates of non-CABG-related major bleeding, mortality, and reinfarction were not different at short-and long-term follow-up ( Table 5 ). In multivariable analysis, iso-osmolar contrast use was associated with increased 30-day rates of MACE (HR, 1.76, 1.13-2.75), but not NACE or major bleeding. However, contrast osmolality was not a significant predictor of long-term outcomes in multivariable analysis.
Discussion
Our analysis of the HORIZONS-AMI supports the association of CI-AKI with more unfavourable short-and long-term cardiovascular and bleeding outcomes, including mortality. It has been thought that this form of acute kidney injury selects patients with increased comorbidities and that the increased rate of adverse outcomes is Potential co-variables in model for NACE and MACE: age, gender, Killip class 2-4 ( vs. 1), baseline TIMI 0/1 flow ( vs. 2/3), left ventricular ejection fraction (per 10% decrease), platelet count (per 100 000 increase), white blood cell count (per 1000 increase), current smoker, baseline haemoglobin (per 1 g/dL decrease), mitral regurgitation 3, 4 ( vs. 1, 2), baseline creatinine (per 1 mg/dL increase), bivalirudin randomization, history of diabetes, hypertension, hyperlipidaemia, diabetes, insulin-treated diabetes, congestive heart failure, peripheral arterial disease, renal insufficiency, renal sufficiency requiring dialysis, major cardiac rhythm/rate disturbance, atrial fibrillation/flutter, prior myocardial infarction, prior PCI, prior CABG, and left anterior descending infarct-related artery. Potential co-variables in model for non-CABG major bleeding: age, gender, Killip class 2-4 ( vs. 1), baseline TIMI 0/1 flow ( vs. 2/3), left ventricular ejection fraction (per 10% decrease), platelet count (per 100 000 increase), white blood cell count (per 1000 increase), current smoker, baseline haemoglobin (per 1 g/dL decrease), mitral regurgitation 3, 4 ( vs. 1, 2), baseline creatinine (per 1 mg/dL increase), bivalirudin randomization, history of diabetes, hypertension, hyperlipidaemia, diabetes, insulin-treated diabetes, congestive heart failure, peripheral arterial disease, renal insufficiency, renal sufficiency requiring dialysis, atrial fibrillation/flutter, prior myocardial infarction, prior PCI, prior CABG, and left anterior descending infarct-related artery. Potential co-variables in model for mortality: age, Killip class 2-4 ( vs. 1), left ventricular ejection fraction, platelet count, baseline haemoglobin, baseline creatinine, white blood cell count, bivalirudin randomization, history of diabetes, prior myocardial infarction, congestive heart failure. CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention.
reflective of those co-morbidities. Furthermore, patients who develop CI-AKI may suffer loss of their residual kidney function, and part of the higher risk for adverse outcomes may be the result of the physiologic burden of chronic kidney disease. However, recent analyses showing that reduced rates of CI-AKI through an intervention reduced the rates of adverse outcomes suggest that there may be a direct causal relationship between CI-AKI and adverse cardiovascular outcomes. 8, 9, 22, 26 Our multivariable analysis further highlights the importance of CI-AKI as a predictor of adverse outcomes. These data support other cohort data that identify acute kidney injury after coronary angiography as associated with increased rates of death at long-term follow-up, even after adjustment for traditional risk factors. 27 Furthermore, these data highlight that the risk persists when those that suffered short-term events were excluded from the analysis, with increased hazard and highly significant divergence in survival curves for MACE and mortality between 30 days and 3 years in our landmark analysis. In the absence of a randomized trial involving a proven and rigorous prevention strategy, it remains difficult to truly ascertain how much of the impact is related to CI-AKI rather than the potential confounding variables mentioned above.
Since CI-AKI is associated with worse clinical outcomes, it is imperative to be able to predict patients at increased risk so preventive strategies can be employed. Previous data have reported on the predictors of CI-AKI in stable PCI or all comer populations, 1, 28 but data analysing predictors of CI-AKI in acute coronary syndromes have had small sample sizes. 29, 30 While it is well known that patients with baseline chronic kidney disease are at high risk, our analysis demonstrates that for all patients, including those without baseline chronic kidney disease analysed separately, age, contrast volume, LAD infarct-related artery, and history of CHF are predictors of CI-AKI. Of the modifiable risk factors, careful attention to contrast volume needs to be a key focus, especially in patients at a higher risk of CI-AKI. Our analyses of the Mehran and Marenzi risk scores demonstrate a significant trend between increasing scores and risk of CI-AKI. Since these scores were applied retrospectively only on patients with the requisite data available, it is possible that predictive value as assessed by the c-statistic would be more accurate if the data had been collected in a prospective manner.
Rates of CI-AKI were similar in our large cohort of STEMI patients, when compared with other analyses of patients with acute coronary syndromes. 22, 23, 31, 32 While risk is higher in the setting of acute myocardial infarction compared with non-urgent PCI, from limited data, it appears risk is similar in STEMI vs. non-STEMI. 30 The increased presence of haemodynamic instability in STEMI patients may be balanced by increased rates of diabetes and older age in NSTEMI patients. In our analysis of the HORIZONS-AMI study, there were no differences in rates of CI-AKI between the low-osmolar and iso-osmolar groups, similar to the results of the most recent randomized controlled trials. 10, 15, 33 In terms of contrast media and cardiovascular outcomes, we found lower rates of NACE, MACE, stent thrombosis, and ischaemic TVR at 30 days with the use of low-osmolar contrast media compared with iso-osmolar contrast media in bivariate analysis. Our multivariable analysis suggested that the use of the isoosmolar contrast, iodixanol, may be associated with higher adverse cardiac events at short-term follow-up only. Clinical trials in this area have been divergent. In the COURT trial, the use of the isoosmolar, non-ionic agent iodixanol, was associated with lower 
rates of in hospital major adverse events than with the use of the low osmolar, ionic agent, ioxaglate. 33 However, other studies have either found no difference between the two agents, or more frequent in hospital MACE with the use of iodixanol. 34, 35 Furthermore, in vitro data have demonstrated an increased pro-thrombotic effect with iodixanol compared with the ionic low-osmolar agent, ioxaglate. 36 Our analysis stratified contrast type by osmolality only, and the lowosmolar group includes the ionic agent, ioxaglate, as well as the other low-osmolar contrast agents used in the trial, which were non-ionic. Thus, our results may be influenced by the interplay between osmolality and ionicity, and their differential effects on both the coagulation cascade and platelet activation. The divergence of the literature cited highlights this as an area where more rigorous study is definitely warranted. Finally, significant attention has been dedicated in studying preventive strategies for CI-AKI; however, few have focused on STEMI patients alone. One large randomized trial by Marenzi et al. 8, 19 demonstrated a dose-dependent reduction in rates of CI-AKI and mortality with the use of N-acetylcysteine; however, this finding was not confirmed in a subsequent study. These findings may have been influenced by the high rate of CI-AKI observed in the control group in the trial, over twice that was observed in our cohort. However, the HORIZONS-AMI trial did not standardize or collect data regarding preventive strategies employed for CI-AKI such as N-acetylcysteine or various hydration protocols, thus, this analysis does not clarify the heterogeneity of results in earlier studies.
Limitations
Several limitations of our study warrant mention. First, our study was not powered to detect differences in outcomes in patients with vs. without CI-AKI, thus all results must be considered hypothesis generating. Second, preventive strategies for CI-AKI were not standardized in the study protocol, and data regarding these measures were not collected in the case report forms, potentially confounding our results. Third, our definition of CI-AKI relied solely on measurements of serum creatinine, which is an imperfect measurement of renal function; no direct urinary markers of tubular dysfunction were collected in this patient population. Furthermore, baseline creatinine values may already reflect impairment from haemodynamic changes in the setting of acute myocardial infarction. Fourth, we may have potentially underestimated the true incidence of CI-AKI for two reasons: our protocol only recommended measurement of serum creatinine for 2 days post-admission unless there was a rise by 0.3 mg/dL, in which case measurement was prolonged, thus, we may have missed later rises in serum creatinine, and if the population had higher rates of cardiogenic shock or Killip class .1, rates of CI-AKI would have likely been higher. Finally, we do not know whether AKI persisted or resolved before hospital discharge, and do not have data regarding need for haemodialysis in patients during or after the index hospitalization.
Conclusions
Contrast-induced acute kidney injury after primary PCI is associated with worse short-and long-term cardiovascular and bleeding outcomes, including mortality. It is a powerful independent predictor of adverse outcomes and mortality. High-risk patients should be identified and targeted for preventive strategies.
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